- BMO reiterates Receptos (RCPT -0.6%) at Outperform.
- "With primary focus on selective S1P1 modulator RPC1063, recent completion of enrollment to the phase 2 portion of the phase 2/3 RADIANCE trial in relapsing MS keeps both the Q4 interim analysis and mid-14 complete analysis on track," analyst Jim Birchenough says, referencing the pipeline update the company provided with its Q3 results.
- Price target hiked slightly to $41 (from $40), representing upside of nearly 62% from current levels.
From other sites
at CNBC.com (Feb 26, 2015)
Video at CNBC.com (Feb 26, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs